DLI indication and disease type
. | No. with indication for DLI . | . | . | ||
|---|---|---|---|---|---|
| Disease . | Residual disease . | Progression/relapse . | Mixed chimerism . | ||
| Myeloma | 11 | 8 | 0 | ||
| Hodgkin lymphoma | 1 | 8 | 4 | ||
| LG-NHL/CLL/PLL | 1/0/0 | 0/0/1 | 6/2/0 | ||
| HG-NHL | 0 | 1 | 2 | ||
| CML | 0 | 1 | 0 | ||
. | No. with indication for DLI . | . | . | ||
|---|---|---|---|---|---|
| Disease . | Residual disease . | Progression/relapse . | Mixed chimerism . | ||
| Myeloma | 11 | 8 | 0 | ||
| Hodgkin lymphoma | 1 | 8 | 4 | ||
| LG-NHL/CLL/PLL | 1/0/0 | 0/0/1 | 6/2/0 | ||
| HG-NHL | 0 | 1 | 2 | ||
| CML | 0 | 1 | 0 | ||
To attain further cytoreduction prior to immunotherapy, 7 patients received specific antitumoral therapy prior to DLI: 3 of these patients had Hodgkin lymphoma, 2 had myeloma, and 1 each had LG-NHL and PLL.